title: Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study.
abstract: OBJECTIVE
  To compare treatment outcome of conventional surgery followed by adjuvant postoperative radiotherapy (PORT) versus concurrent chemoradiation therapy (cCRT) for stage IIB cervical carcinoma.
  
  
  METHODS
  A retrospective analysis was conducted of 59 patients with stage IIB uterine cervical cancer treated with radical surgery plus PORT (N = 34) or cCRT-alone (N = 25) from April 1996 to June 2008. The median follow-up time was 27 months (range, 3-150 months) in the cCRT group and 44 months (range, 4-134 months) in the PORT group. The median age was 59 years (range, 37-85 years) in the cCRT group and 49 years (range, 32-74 years) in the PORT group. All 34 patients in the surgery group underwent hysterectomy with pelvic lymph node dissection and received PORT. Twenty-five patients (42%) were assigned to the cCRT group.
  
  
  RESULTS
  The 3-year overall survival rates for surgery plus PORT and cCRT-alone were 80.0% and 75.1%, respectively. The difference between these 2 treatments was not statistically significant (log-rank P = 0.5871). The late complication rate of grade 3-4 was 12% in the cCRT group and 26% in the surgery group.
  
  
  CONCLUSIONS
  This retrospective study suggests that survival results with cCRT and with conventional surgery plus PORT for patients with stage IIB cervical carcinoma are comparable.
authors.affiliation: Department of Radiology, University of Tokyo Hospital, Japan. yamashitah-rad@h.u-tokyo.ac.jp
authors.forename: Hideomi
authors.initials: H
authors.lastname: Yamashita
authors.forename: Kae
authors.initials: K
authors.lastname: Okuma
authors.forename: Kei
authors.initials: K
authors.lastname: Kawana
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Oda
authors.forename: Tetsu
authors.initials: T
authors.lastname: Yano
authors.forename: Shino
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Reiko
authors.initials: R
authors.lastname: Wakui
authors.forename: Kuni
authors.initials: K
authors.lastname: Ohtomo
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakagawa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*